| Literature DB >> 30891116 |
Simona Bungau1, Mohamed M Abdel-Daim2,3, Delia Mirela Tit1, Esraa Ghanem4, Shimpei Sato3, Maiko Maruyama-Inoue3, Shin Yamane3, Kazuaki Kadonosono3.
Abstract
Oxidative stress and inflammation play a critical role in the initiation and progression of age-related ocular abnormalities as cataract, glaucoma, diabetic retinopathy, and macular degeneration. Therefore, phytochemicals with proven antioxidant and anti-inflammatory activities, such as carotenoids and polyphenols, could be of benefit in these diseases. We searched PubMed and Web of Science databases for original studies investigating the benefits of different carotenoids and polyphenols in age-related ophthalmic diseases. Our results showed that several polyphenols (such as anthocyanins, Ginkgo biloba, quercetin, and resveratrol) and carotenoids (such as lutein, zeaxanthin, and mezoxanthin) have shown significant preventive and therapeutic benefits against the aforementioned conditions. The involved mechanisms in these findings include mitigating the production of reactive oxygen species, inhibiting the tumor necrosis factor-α and vascular endothelial growth factor pathways, suppressing p53-dependent apoptosis, and suppressing the production of inflammatory markers, such as interleukin- (IL-) 8, IL-6, IL-1a, and endothelial leucocyte adhesion molecule-1. Consumption of products containing these phytochemicals may be protective against these diseases; however, adequate human data are lacking. This review discusses the role and mechanisms of polyphenols and carotenoids and their possible synergistic effects on the prevention and treatment of age-related eye diseases that are induced or augmented by oxidative stress and inflammation.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30891116 PMCID: PMC6390265 DOI: 10.1155/2019/9783429
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Summarization of the implications of oxidative stress in age-related ocular diseases and effects of phytochemicals.
Figure 2Classification of main polyphenols investigated for age-related eye diseases and their natural sources.
Effects of some polyphenols on age-related eye diseases in human studies.
| Polyphenols | Natural source/dose | Cell type/type of study | Effects on chronic eye diseases | Ref |
|
|---|---|---|---|---|---|
| Anthocyanins | Bilberry | Retinal pigment epithelial cells (AREP 19) | Mediate a detergent-like perturbation of cell membranes and light-induced damage to the cell | [ | |
|
| |||||
| EGCG | 10, 25, 50, 75, 100, and 150 | Human lens epithelial HLEB-3 cells | EGCG protects HLE cells from the mitochondria-mediated apoptosis (induced by H2O2 through the modulation of caspases, Bcl-2 family, and MAPK & Akt pathways) | [ | |
| 3 months | Human patients/placebo-controlled, double-blind, crossover design | Neuroprotective function pattern-evoked electroretinograms increased in amplitude Favorable influence in inner retinal function in the eyes with early to moderately advanced glaucomatous damage | [ | <0.01 | |
| 20 and 40 mM | Human RPE cell line ARPE-19 | AMD and DR prevention | [ | ||
| 20 and 40 mM | Human retinal vascular endothelial cell (HREC) (case of diabetes) | Inhibits the expression of vascular endothelial growth factor (VEGF) | [ | <0.01 | |
|
| |||||
|
| 40 mg GBE 2 times daily for 6 months | Human patients/experimental study, prospective, double blind | No significant changes were found in intraocular pressure and optic nerve head | [ | >0.01 |
| Ginkgo biloba extract (40 mg, 3 times per day 4-week phases/8 weeks washout period) | Human patients/prospective, randomized, placebo-controlled crossover study | Changes in visual field and contrast sensitivity did not differ by treatment received or sequence | [ | >0.2 | |
| 80 mg GBE 2 times daily | Human patients/retrospective study | Slowed the progression of visual field damage in patients with normal tension glaucoma | [ | ||
| 80 mg GBE orally, twice a day for four weeks | Human patients/prospective, randomized, placebo study | Desirable effect on ocular blood flow in normal tension glaucoma patients | [ | ||
| 40 mg, 3 times per day 4-week phases/8 weeks washout period/4 weeks of placebo treatment | Human patients/prospective, randomized, placebo-controlled, double-masked crossover trial | Improves preexisting visual field damage in some patients with normal tension glaucoma | [ | ||
| Human patients/retrospective analysis | May be helpful in improving visual function in some individuals with NTG | [ | |||
| Ginkgo biloba extract (EGB761) and ginkgolide B | Retina explants | Protecting RGCs against apoptosis | [ | ||
|
| |||||
| Quercetin | 50 | Cultured human RPE cells | AMD prevention | [ | <0.001 |
| 50 | Cultured human RPE cells (ARPE-19) | AMD prevention | [ | ||
|
| |||||
| Resveratrol | Human lens epithelial cells | Cataract prevention | [ | ||
| 5 and 10 mg/kg/day, 1 to 7 months | High-glucose culture Müller-treated cells | It is a therapeutic option to prevent diabetic retinopathy | [ | <0.05 | |
| Longevinex | Human patients | Efficacy against AMD | [ | ||
Effects of some polyphenols on age-related eye diseases in animals.
| Polyphenols | Natural source/dose/period | Cell type/animal model | Effects in chronic eye diseases | Ref |
| |
|---|---|---|---|---|---|---|
| Anthocyanins | Grape skin | Sprague Dawley (SD) rat lens organ culture system | Inhibits selenite-induced cataractogenesis | [ | ||
| Bilberry | Retinal pigment epithelium (RPE) cells | Inhibits AMD | [ | |||
| Blueberry; STZ, 60 mg/kg; and blueberry anthocyanins at 20, 40, and 80 mg/kg were given orally, 12 weeks | Rat retinas, male rats, 5 groups | It can protect retinal cells from diabetes-induced oxidative stress and inflammation, and this may be regulated through Nrf2/HO-1 signaling | [ | |||
| Bilberry ( | Streptozotocin-induced diabetic SD rats | Prevention of diabetic retinopathy using a dietary bilberry supplement | [ | |||
| Seed coat of black soybean 50 mg/kg daily, orally, for 1, 2, and 4 weeks after intraperitoneal injection of N-methyl-N-nitrosourea (MNU) | Animal model of retinal degeneration | Reduce retinal degeneration | [ | |||
| Maqui berry ( | Murine photoreceptor cells (661 W) | Suppress the light-induced photoreceptor cell death by inhibiting ROS production; the inhibition of phosphorylated-p38 may be involved in the underlying mechanism | [ | |||
| Dried cornelian cherry ( | New Zealand white rabbits, aged between 6-12 months, were used: 7 males and 7 females | Intraocular pressure (IOP)—hypotensive effect for loganic acid (0.7%)—could be compared with the widely ophthalmologically used timolol | [ | |||
|
| ||||||
| EGCG | Green tea leaf extract ( | Enucleated rat lenses | Inhibits selenite-induced cataractogenesis | [ | ||
| Intraperitoneal (25 mg/kg) intraocular (5 | Rat retinal neurons | Glaucoma prevention | [ | |||
| 20 and 40 mM | Animal models | Significantly reduced vascular leakage and permeability by blood-retinal barrier breakdown in VEGF-induced animal models | [ | |||
| Nontoxic optimal concentration of EGCG used for the treatment of HCECs in vitro was 10 | Rabbit DES model | Topical treatment with AT plus E10/HA increased tear secretion, reduced corneal epithelial damage, and maintained the epithelial layers and stromal structure | [ | |||
|
| ||||||
| Ginkgo biloba | 5 | Rabbits aged 7 weeks | Suppressed steroid-induced IOP elevation; it seems to prevent the adverse effects of DEX on TM cells | [ | ||
|
| ||||||
| Quercetin | Quercetin 10 | Rat lens | Cataract prevention | [ | ||
| The expression levels of BDNF, NGF, TrkB, synaptophysin, Akt, Bcl-2, cytochrome c, and caspase-3 using Western blotting techniques with and without QCT treatments were quantitated and compared with those of nondiabetic rats | Diabetic rat retina | Significant increase in the level of neurotrophic factors and inhibited the level of cytochrome c and caspase-3 activity | [ | |||
|
| ||||||
| Quercetin and resveratrol | 0.01% QCT, 0.1% RES, 0.01% QCT + 0.1% RES (QCT + RES), or vehicle was topically applied | Desiccating stress (DS) mouse model | Reduced corneal staining in DS-exposed mice | [ | QCT | <10−3 |
| IL-1 | <0.05, 0.01, and 0.01 | |||||
| CD4+ T cells increased in recipients of DS-exposed mice and were lower in recipients of QCT- and RES-treated mice | <0.05, <0.05 | |||||
| The anti-inflammatory effect of QCT, RES, and QCT + RES on DED experimental model suggests that their topical application could be used for DED treatment | ||||||
| 25 mg/kg/day quercetin by intraperitoneal injection daily, 2 months | Ccl2/Cx3cr1 double knockout (DKO) mice | Does not improve the retinal AMD-like lesions in the Ccl2(−/−)/Cx3cr1(−/−) (due to its insufficient suppression of the inflammatory and apoptosis pathways in the eye) | [ | |||
| Quercetin 33.63 mg/kg/day and chlorogenic acid | Pigmented rabbits | AMD prevention | [ | <0.05 | ||
|
| ||||||
| Resveratrol | 40 mg/kg | 48 SD rat lens | Inhibits selenite-induced cataractogenesis | [ | ||
| 25 | Porcine TM cells | Preventing or delaying of the abnormalities of the TM | [ | |||
| 4 months oral resveratrol administration (5 mg/kg/day) | Streptozotocin-induced diabetic Wistar rats | Therapeutic supplement to prevent from diabetic retinopathy | [ | |||
| 1 month after the 5th injection of streptozotocin or buffer—20 mg/kg, daily, for 4 weeks, and all mice were killed 2 months after the injections | Streptozotocin-induced diabetic C57BL/6 mice | Prevent diabetic retinopathy | [ | |||
| 10 mg/kg 30 days | 24 streptozotocin-induced diabetic Wistar albino male rats | Prevent diabetic retinopathy | [ | |||
| 5 mg/kg per day for 4 months | Streptozotocin-induced diabetic Wistar albino male rats | Prevent diabetic retinopathy | [ | |||
| 5 and 10 mg/kg/day, 1 to 7 months | Diabetic rat retina | Prevent diabetic retinopathy | [ | |||
Effects of some carotenoids on age-related eye diseases.
| Carotenoid | Characteristics of the study | Cell type/animal model | Effects in chronic eye diseases | Ref. |
|---|---|---|---|---|
| Lutein and zeaxanthin | Multicenter, randomized, double-masked, placebo-controlled phase 3 study with a 2 × 2 factorial design (2006–2012) | 4203 human patients, age 50-85 years | Median follow-up: 5 years, with 1940 study eyes, 1608 participants, progressing to advanced AMD | [ |
| Prospective study, in 1980 | Human patients (female), age 45-71 years | Decrease the risk of cataracts, | [ | |
| Prospective study, in 1986 | 36644 human patients (male), age 45-75 years | May decrease the risk of cataracts severe enough to require extraction; this relation appears modest in magnitude | [ | |
| 1354 people eligible, 246 developed a nuclear cataract (level 4 or 5 opacity) | Human patients, adults aged 43-84 years | Decrease the risk of nuclear cataracts | [ | |
| Usual nutrient intake = average intake from 5 food frequency questionnaires (were collected during a 13- to 15-year period before the evaluation of lens opacities). The duration of vitamin supplement use was determined from 7 questionnaires collected during this same period | 478 human patients (nondiabetic female), aged 53-73 years | Prevention of age-related cataract | [ | |
| Study for individual carotenoids and tocopherols in serum, quality-controlled HPLC method | 138 human patients with senile cataracts | No association | [ | |
|
| ||||
| Macular pigments | The optical density of MP was measured psychophysically | 46 subjects, age 21-81 years with healthy maculae and in 9 healthy eyes known to be at high risk of AMD | Decrease the risk of AMD age-related decline (optical density of MP) at volunteers with no ocular disease (right eye: r(2) = 0.29, | [ |
| Lutein (L) and zeaxanthin (Z) extracted from each tissue sample were determined by HPLC | 56 donors with AMD and 56 controls were cut into 3 concentric regions centered on the fovea | The results are inconsistent with a model that attributes a loss of L and Z in the retina to the destructive effects of AMD | [ | |
| The relative risk for AMD—estimated according to dietary indicators of antioxidant status, controlling risk factors (smoking), by using multiple logistic regression analyses | 356 case subjects, diagnosed with the advanced stage of AMD within 1 year prior to their enrollment, aged 55-80 years | Increasing the consumption of foods rich in certain carotenoids (dark-green, leafy vegetables) may decrease the risk of developing advanced or exudative AMD | [ | |
|
| ||||
| Lutein | Measuring macular pigment optical density (MPOD) and retinal sensitivity | 20 patients with medium/large drusen, 19 with RPD, and 15 control subjects | The mean MPOD significantly increased in RPD ( | [ |
|
| ||||
| Lutein and zeaxanthin | Dietary intake | People over age 40 years ( | No association with AMD | [ |
| Dietary intake + supplement intake of antioxidant vitamins and zinc at baseline and the 5-year incidence of early age-related maculopathy | During 1992-1994, 3654 people, aged > 49 years (82% of those are eligible) were examined for the Blue Mountains Eye Study baseline | No evidence of protection associated with dietary antioxidant or zinc intakes | [ | |
|
| ||||
| Lutein + lycopene | Dietary intake | 111 individuals with type 2 diabetes in a community-based study | Modulation of retinopathy risk | [ |
|
| ||||
| Zeaxanthin | Diet supplemented with 0.02% or 0.1% Zx | Age-matched normal rats | Inhibits diabetic retinopathy | [ |
|
| ||||
| Lutein | Lutein, lutein + insulin 12 weeks | Streptozotocin-induced diabetic rats | Preventing the development of cataracts | [ |
|
| ||||
| Carotenoids and vitamins A, C, and E | Multicenter (5 ophthalmology centers in the USA) eye disease case control study | 356 case subjects, diagnosed with an advanced stage of AMD within 1 year prior to their enrollment, aged 55 to 80 years, and residing near a participating clinical center | Dietary intake of carotenoids associated with a lower risk for AMD | [ |